Chengdu Kanghong Pharmaceutical Group Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Xiao Ke
Chief executive officer
CN¥2.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 14.6yrs |
| CEO ownership | 8.7% |
| Management average tenure | no data |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
CEO
Xiao Ke (41 yo)
14.6yrs
Tenure
CN¥2,045,500
Compensation
Mr. Xiao Ke serves as a General Manager and President of Chengdu Kanghong Pharmaceuticals Group Co., Ltd., and Director since June 21, 2010 and served as Vice President.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM, President & Director | 14.6yrs | CN¥2.05m | 8.73% CN¥ 1.5b | |
| VP & Director | 8.3yrs | CN¥5.85m | 0.038% CN¥ 6.7m | |
| VP & Director | 16.6yrs | CN¥1.43m | 1.15% CN¥ 201.6m | |
| Non-Independent Director | 13.6yrs | no data | no data | |
| Independent Director | 1.4yrs | CN¥50.00k | no data | |
| Non-Independent Director | 1.4yrs | no data | no data | |
| Employee Representative Supervisor | 5.1yrs | no data | 0.0016% CN¥ 285.8k | |
| Chairman of the Board | 23.9yrs | CN¥1.32m | 22.58% CN¥ 4.0b | |
| Chairman of the Supervisory Board | 13.6yrs | no data | 3.55% CN¥ 621.9m | |
| Employee Supervisor | 5.1yrs | no data | no data | |
| Independent Director | 1.4yrs | CN¥50.00k | no data | |
| Independent Director | 1.4yrs | CN¥50.00k | no data |
6.7yrs
Average Tenure
54yo
Average Age
Experienced Board: 002773's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 05:29 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chengdu Kanghong Pharmaceutical Group Co., Ltd is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weiya Zhang | BOCI Research Ltd. |
| Yue Gao | Changjiang Securities Co. LTD. |
| Ziyu He | China International Capital Corporation Limited |